First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial

First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial

Minetta C Liu,1 Wolfgang Janni,2 Vassilis Georgoulias,3 Denise A Yardley,4 Nadia Harbeck,5 Xin Wei,6 Desmond McGovern,7 Robert Beck7 1Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; 2Department of Obstetrics and Gynecology, University Clinic Ulm, Ulm, Germany; 3Depa...

Full description

Bibliographic Details
Main Authors: Liu MC, Janni W, Georgoulias V, Yardley DA, Harbeck N, Wei X, McGovern D, Beck R
Format: Article
Language:English
Published: Dove Medical Press 2019-12-01
Series:Cancer Management and Research
Subjects:
metastatic triple-negative breast cancer
circulating tumor cells
nab-paclitaxel
chemotherapy
prognosis.
Online Access:https://www.dovepress.com/first-line-doublet-chemotherapy-for-metastatic-triple-negative-breast--peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/first-line-doublet-chemotherapy-for-metastatic-triple-negative-breast--peer-reviewed-article-CMAR

Similar Items